Investigating zero transmission of HIV in the MSM population: a UK modelling case study.

HIV policy HIV/AIDS PrEP Prevention Public health Zero transmission

Journal

Archives of public health = Archives belges de sante publique
ISSN: 0778-7367
Titre abrégé: Arch Public Health
Pays: England
ID NLM: 9208826

Informations de publication

Date de publication:
20 Nov 2023
Historique:
received: 28 04 2023
accepted: 31 08 2023
medline: 21 11 2023
pubmed: 21 11 2023
entrez: 21 11 2023
Statut: epublish

Résumé

UNAIDS 90-90-90 goals for HIV have been surpassed in the UK, with focus now moving to ending transmission by 2030. The concept of zero transmission is complex and many factors can influence transmission. We aimed to investigate how the target of zero transmission might be reached in the UK. We developed a de novo Markov state transition open cohort model of HIV with a 50-year time horizon, which models six key screening, treatment and prevention parameters, including treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP). We studied the anticipated HIV epidemic trajectory over time in men who have sex with men (MSM), with and without changing the six key parameters, defining zero transmission as a 60% reduction in incidence compared with 2010 incidence. Zero transmission in the MSM population was not achieved within the model's time horizon in our base case scenario, when the six key parameters were set to their 2019 values. Several future scenarios were explored, including a combination approach to preventing HIV transmission through increasing five key parameter values and considering three different TasP values; zero transmission was achieved by 2030 in the scenario where TasP was increased from its current level of 97-99%, avoiding 48,969 new HIV cases over the time horizon and reducing the lifetime risk of acquiring HIV for HIV-negative MSM not using PrEP from 13.65 to 7.53%. Zero transmission in the UK MSM population can be reached by the target year of 2030 with bold changes to HIV policy. A combination approach such as the UK Government's 'Towards Zero' Action plan, impacting multiple policies and including an increase in TasP, has the potential to achieve meaningful reductions in HIV transmission and meet this ambitious goal.

Sections du résumé

BACKGROUND BACKGROUND
UNAIDS 90-90-90 goals for HIV have been surpassed in the UK, with focus now moving to ending transmission by 2030. The concept of zero transmission is complex and many factors can influence transmission. We aimed to investigate how the target of zero transmission might be reached in the UK.
METHODS METHODS
We developed a de novo Markov state transition open cohort model of HIV with a 50-year time horizon, which models six key screening, treatment and prevention parameters, including treatment-as-prevention (TasP) and pre-exposure prophylaxis (PrEP). We studied the anticipated HIV epidemic trajectory over time in men who have sex with men (MSM), with and without changing the six key parameters, defining zero transmission as a 60% reduction in incidence compared with 2010 incidence.
RESULTS RESULTS
Zero transmission in the MSM population was not achieved within the model's time horizon in our base case scenario, when the six key parameters were set to their 2019 values. Several future scenarios were explored, including a combination approach to preventing HIV transmission through increasing five key parameter values and considering three different TasP values; zero transmission was achieved by 2030 in the scenario where TasP was increased from its current level of 97-99%, avoiding 48,969 new HIV cases over the time horizon and reducing the lifetime risk of acquiring HIV for HIV-negative MSM not using PrEP from 13.65 to 7.53%.
CONCLUSIONS CONCLUSIONS
Zero transmission in the UK MSM population can be reached by the target year of 2030 with bold changes to HIV policy. A combination approach such as the UK Government's 'Towards Zero' Action plan, impacting multiple policies and including an increase in TasP, has the potential to achieve meaningful reductions in HIV transmission and meet this ambitious goal.

Identifiants

pubmed: 37986184
doi: 10.1186/s13690-023-01178-0
pii: 10.1186/s13690-023-01178-0
pmc: PMC10659044
doi:

Types de publication

Journal Article

Langues

eng

Pagination

201

Informations de copyright

© 2023. The Author(s).

Références

Lancet HIV. 2017 Oct;4(10):e465-e474
pubmed: 28768604
Am J Public Health. 2021 Jan;111(1):150-158
pubmed: 33211582
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
Lancet HIV. 2021 Jul;8(7):e440-e448
pubmed: 34118196
HIV Med. 2019 Nov;20(10):699-703
pubmed: 31424598
Lancet. 2016 Jan 2;387(10013):53-60
pubmed: 26364263
Lancet Infect Dis. 2018 Jan;18(1):85-94
pubmed: 29054789
Lancet Public Health. 2021 Oct;6(10):e739-e751
pubmed: 34563281
N Engl J Med. 2015 Aug 27;373(9):808-22
pubmed: 26193126
Curr Opin HIV AIDS. 2016 Jan;11(1):74-9
pubmed: 26599164

Auteurs

Katherine Massey (K)

Costello Medical, 50/60 Station Road, Cambridge, CB1 2JH, UK. katherine.massey@costellomedical.com.

Vittoria Vardanega (V)

Costello Medical, 55 Old Broad Street, London, EC2M 1RX, UK.

Mas Chaponda (M)

Hamad Medical Corporation, Doha, Qatar.

Lucy A Eddowes (LA)

Costello Medical, 50/60 Station Road, Cambridge, CB1 2JH, UK.

Natalie Hearmon (N)

Costello Medical, 55 Old Broad Street, London, EC2M 1RX, UK.

Classifications MeSH